Taking the Tablet Ahead of Intercourse
Placeholder: dosing window sits roughly one to three hours pre-activity.
- 1–3 h: Recommended window (placeholder pre-dose timing)
- 30–60 mg: Dose range (placeholder strength options)
- On-demand: Use pattern (placeholder, not daily)
- Delayed Tmax: Food effect (placeholder with high-fat meal)
Why timing matters
Placeholder: correct timing aligns peak drug levels with activity.
Placeholder highlight: dosing too early or late reduces benefit.
Rapid Gastrointestinal Absorption
Placeholder: fast absorption rate constant drives quick concentration rise.
- 2.0 /h: Absorption rate (ka) (placeholder model constant)
- ~30–60 min: Onset of action (placeholder clinical estimate)
- ~42%: Bioavailability (placeholder oral fraction)
- >99%: Protein binding (placeholder plasma binding)
Absorption kinetics
Placeholder: concentration rises steeply during first hour post-dose.
Placeholder highlight: rapid rise distinguishes it from chronic SSRIs.
Peak Plasma Concentration (Cmax)
Placeholder: maximum concentration occurs about one to two hours post-dose.
- ~1.0–1.3 h: Tmax (placeholder model output)
- ~310 ng/mL: Cmax (60mg) (placeholder reference value)
- Aligned with Tmax: Effect peak (placeholder timing overlap)
- Roughly linear: Dose linearity (placeholder scaling assumption)
Peak and window overlap
Placeholder: peak timing is designed to overlap intercourse window.
Placeholder highlight: overlap of peak and activity maximizes benefit.
Rapid Elimination Phase
Placeholder: short elimination half-life clears drug within about a day.
- ~1.5 h: Elimination half-life (placeholder terminal t½)
- ~24 h: Near-full clearance (placeholder time estimate)
- Minimal: Accumulation risk (placeholder, no daily dosing)
- CYP3A4/2D6: Metabolism (placeholder hepatic pathway)
Fast washout profile
Placeholder: rapid elimination limits next-day residual effects.
Placeholder highlight: short exposure window reduces side-effect burden.
On-Demand vs. Chronic Daily SSRIs
Placeholder: chronic SSRIs build steady-state levels over weeks, unlike this drug.
- 20–36 h: Chronic SSRI t½ (placeholder typical daily SSRI)
- Not reached: Steady state (placeholder for on-demand use)
- Very low: Discontinuation risk (placeholder vs. chronic use)
- Event-based: Dosing pattern (placeholder vs. once-daily)
Contrasting exposure profiles
Placeholder: flat chronic baseline contrasts with this sharp on-demand spike.
Placeholder highlight: no accumulation avoids chronic steady-state effects.